Atara Biotherapeutics (ATRA) Preferred Stock Liabilities (2013 - 2014)
Atara Biotherapeutics (ATRA) posted Preferred Stock Liabilities of $74.6 million for Q3 2014, up 22.07% on a QoQ basis from $61.1 million in Q4 2013.
Atara Biotherapeutics (ATRA) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends
Atara Biotherapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $74.6 million for Q3 2014.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $74.6 million in Q3 2014, while the trailing twelve-month figure through Sep 2014 was $74.6 million (changed N/A YoY) and the FY2013 annual result came in at $61.1 million, up 1135.16% from the prior year.
- Preferred Stock Liabilities was $74.6 million for Q3 2014 at Atara Biotherapeutics, up from $61.1 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $74.6 million in Q3 2014 and bottomed at $61.1 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Atara Biotherapeutics | 110.04 Mn | 101.68 Mn | 392,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2014 | 74.57 Mn |
| Dec 31, 2013 | 61.09 Mn |